Arsenal Capital Partners has acquired Cello Health

Arsenal Capital Partners has acquired Cello Health for one-hundred and eighty-one million pounds. The deal will give Arsenal the basis for a new enterprise to enable its bio pharmaceutical and healthcare clients to maximise the value of their products.

CEO of Arsenal’s new planned enterprise, Jon Williams, stated: “We are creating an enterprise that supports better strategic decisions, generates robust data and evidence, undertakes advanced analytics to draw out critical insights and supports communication with a range of critical stakeholders. We look forward to working with our new colleagues as we embark on the next important phase of our journey.”

CEO of Cello Health, Mark Scott, stated: “Today’s announcement marks an exciting moment for Cello Health. We have a shared belief with Arsenal that clients need a partner that combines industry expertise, commercial experience, scientific depth and cutting edge technology and data. We’re confident that we can accelerate growth by expanding support for our clients, investing in innovation and continuing our ambition to become a world class, truly global company.”